Readoutin 104d
Celltrion — CT-P44(Daratumumab)
Phase 3 primary completion: A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Refractory or Relapsed Multiple Myeloma